Efficacy and Safety of Rescue Treatment with Plasma Exchange in Patients with Acute Inflammatory Neurological Disorders: A Single Center Experience.

CIDP NMOSD adverse events effectiveness intravenous immunoglobulin multiple sclerosis myasthenia gravis pathogenetic antibodies plasma exchange rescue therapy

Journal

Neurology international
ISSN: 2035-8385
Titre abrégé: Neurol Int
Pays: Switzerland
ID NLM: 101551564

Informations de publication

Date de publication:
10 Jul 2024
Historique:
received: 29 05 2024
revised: 03 07 2024
accepted: 08 07 2024
medline: 26 7 2024
pubmed: 26 7 2024
entrez: 25 7 2024
Statut: epublish

Résumé

Therapeutic plasma exchange (TPE) is a highly effective rescue treatment for patients with acute exacerbation of neuroimmunological disease that removes circulating autoantibodies and inflammatory components from the bloodstream. The aims of this study are to explore the safety and the effectiveness of TPE in patients with autoimmune neurological disorders. We retrospectively evaluated the frequency of adverse events (AEs) and the effectiveness of TPE using the modified Ranking Scale (mRS) in patients with acute neurological flares who underwent TPE at the University Hospital of Palermo. Of 59 patients, the majority underwent TPE due to multiple sclerosis (MS) relapse. In 23.7% of cases, TPE was performed before obtaining a definite diagnosis due to the severity of the clinical presentation. After TPE, the mRS score was globally reduced ( These results highlight the early use of TPE in patients with circulating pathogenetic antibodies as well as its favorable safety profile.

Sections du résumé

BACKGROUND BACKGROUND
Therapeutic plasma exchange (TPE) is a highly effective rescue treatment for patients with acute exacerbation of neuroimmunological disease that removes circulating autoantibodies and inflammatory components from the bloodstream. The aims of this study are to explore the safety and the effectiveness of TPE in patients with autoimmune neurological disorders.
METHODS METHODS
We retrospectively evaluated the frequency of adverse events (AEs) and the effectiveness of TPE using the modified Ranking Scale (mRS) in patients with acute neurological flares who underwent TPE at the University Hospital of Palermo.
RESULTS RESULTS
Of 59 patients, the majority underwent TPE due to multiple sclerosis (MS) relapse. In 23.7% of cases, TPE was performed before obtaining a definite diagnosis due to the severity of the clinical presentation. After TPE, the mRS score was globally reduced (
CONCLUSIONS CONCLUSIONS
These results highlight the early use of TPE in patients with circulating pathogenetic antibodies as well as its favorable safety profile.

Identifiants

pubmed: 39051217
pii: neurolint16040056
doi: 10.3390/neurolint16040056
doi:

Types de publication

Journal Article

Langues

eng

Pagination

761-775

Auteurs

Salvatore Iacono (S)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.
Multiple Sclerosis Center, Foundation Institute G. Giglio, Cefalù, 90015 Palermo, Italy.

Giuseppe Schirò (G)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.
Multiple Sclerosis Center, Foundation Institute G. Giglio, Cefalù, 90015 Palermo, Italy.

Giuseppe Salemi (G)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.

Elisabetta Scirè (E)

Trasfusional Medicine Unit, University Hospital Policlinico P. Giaccone, 90129 Palermo, Italy.

Paolo Aridon (P)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.

Michele Melfa (M)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.

Michele Andolina (M)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.

Gabriele Sorbello (G)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.

Andrea Calì (A)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.

Filippo Brighina (F)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.

Marco D'Amelio (M)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.

Paolo Ragonese (P)

Department of Biomedicine, Neuroscience and Advanced Diagnostics, University of Palermo, 90129 Palermo, Italy.

Classifications MeSH